• Montega reiterated its Buy rating on AlzChem on Oct. 30, 2026, maintaining a 12-month price target of EUR 220.
• The research firm flagged uncertainty over the US nitroguanidine project, which is undergoing cost and planning optimization.
• Montega viewed the roughly EUR 600 million annual revenue target as ambitious, requiring nearly 14% fourth-quarter growth.
• Third-quarter EBITDA fell 3.5% to EUR 28.7 million amid higher energy and raw material costs alongside capacity startup expenses.
• The analysts considered the growth case intact, citing progress on German nitroguanidine and creatine capacity expansions.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. AlzChem Group AG published the original content used to generate this news brief via EQS News (Ref. ID: rc_27244) on October 30, 2026, and is solely responsible for the information contained therein.